A Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT07461181 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced or Metastatic Solid Tumors

Interventions

BIOLOGICAL: CS01 (an anti-OX40 antibody)

Sponsor

Ruijin Hospital

Collaborators

[object Object]